An observational study in Sepsis, Acute Kidney Injury Due to Sepsis and Gastrointestinal Microbiome, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 6 sites in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by First Affiliated Hospital of Zhejiang University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 286 studies in Sepsis with a site in China — 99 open to participants now, 106 under way, 5 of them phase 3. Sepsis · China.
Among the 286 studies in Sepsis with a site in China, this one is the 29th largest by planned enrollment of the 164 observational ones that give a count, is one of 33 that started in 2026, is one of 165 observational ones, reaches primary completion later than 101 of the 105 other live ones, and was the 269th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →99 of the 286 studies in Sepsis with a site in China are open now. Recruiting first, the newest first:
Nanjing University · Sites in China
Ages 18+ · Healthy volunteers
Sir Run Run Shaw Hospital · Sites in China
Ages 18+ · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Southeast University, China · Sites in China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–80 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
286 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 19 · Phase 3 15 · Phase 4 17
First in 2004; this study’s year is marked. 33 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 118 across the 121 interventional studies, 180 across the 164 observational. Of the 87 that completed or were terminated, 1 (1%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 286 have an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital of Zhejiang University is the lead sponsor of 264 studies on the registry; 145 are open to participants now.
First Affiliated Hospital of Zhejiang University has 4 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
26 of the studies in Sepsis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089186Phase 3Qilu Pharmaceutical Co., Ltd.Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections | 2026-12 |
| NCT05623722Jing Cai, MDErector Spinae Plane Block Improves Organ Dysfunction in Septic Patients With Acute Gastrointestinal Injury | 2026-11-30 |
| NCT07367113Ying WangPeripheral Perfusion Index-guided Fluid Resuscitation for Preventing Acute Skin Failure in Elderly Critically Ill Patients | 2026-12 |
| NCT07413094Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | 2026-12 |
| NCT07950943Nanjing UniversityAI Treatment Recommendations With Predicted Consequences for Sepsis Fluid and Vasopressor Decisions | 2026-12-01 |
Add all 26 to your calendar (.ics) → With an account.
Among the 286 studies in Sepsis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sepsis is a major cause of morbidity and mortality in intensive care units. Sepsis-associated liver injury (SALI) and sepsis-associated acute kidney injury (S-AKI) are common complications associated with adverse clinical outcomes. Altered gut microbial diversity, microbial metabolites, intestinal barrier dysfunction, and systemic inflammation may contribute to hepato-renal injury during sepsis. However, prospective longitudinal evidence in patients with SALI and S-AKI remains limited.
This prospective, multicenter, longitudinal observational cohort study will enroll adult patients with sepsis across eight intensive care units at six medical centers and healthy adult volunteers as a baseline reference cohort. For patients with sepsis, stool and blood samples will be collected on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis. Healthy volunteers will provide a single baseline stool and blood sample at enrollment. Fecal microbial alpha diversity and community structure will be assessed by metagenomic sequencing and bioinformatic analysis. Plasma metabolites, including total short-chain fatty acids, indoxyl sulfate, and additional targeted plasma metabolites, will be measured by ultra-high-performance liquid chromatography-tandem mass spectrometry. Intestinal barrier and clinical biomarkers will also be assessed.
The primary objectives are to evaluate the associations between longitudinal trajectories of fecal microbial alpha diversity, measured by the Shannon diversity index, and the occurrence of SALI and S-AKI within 7 days after sepsis diagnosis. Secondary objectives include evaluating the associations between longitudinal changes in fecal microbial beta diversity and the occurrence of SALI and S-AKI; assessing the associations between longitudinal trajectories of fecal microbial alpha diversity and organ recovery status at Days 14-20 among patients who develop SALI or S-AKI; describing selected plasma metabolite and intestinal biomarker concentrations at prespecified time points; and assessing 28-day all-cause mortality. Exploratory multi-omics analyses will evaluate microbial taxa, microbial functional genes, metabolites, and host biomarkers to identify candidate biomarkers and biological pathways associated with the development and clinical course of sepsis-associated hepato-renal injury.
The study population comprises two distinct groups recruited from multiple clinical centers. The primary clinical cohort consists of critically ill adult patients (aged ≥18 years) admitted to the Intensive Care Unit (ICU) who are diagnosed with sepsis according to the Sepsis-3 criteria and enrolled within 24 hours after sepsis diagnosis. This cohort will be longitudinally monitored to evaluate changes in the gut microbiome, the occurrence of sepsis-associated liver injury (SALI) and sepsis-associated acute kidney injury (S-AKI) from Day 0 through Day 7 after sepsis diagnosis, and subsequent organ recovery status at Days 14-20 among patients who develop SALI and/or S-AKI. A baseline reference cohort consists of healthy adult volunteers recruited from the community. These volunteers have no history of chronic underlying diseases or recent antibiotic/probiotic use and serve to establish baseline reference profiles for the gut microbiome and circulating metabolites.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-
For Sepsis Patients:
For Healthy Volunteers:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult patients (age ≥18 years) admitted to the ICU who meet the Sepsis-3 diagnostic criteria are enrolled within 24 hours after sepsis diagnosis. This cohort will be longitudinally monitored with biospecimen collection at four time points (Day 0, Days 3-5, Days 7-10, and Days 14-20). Based on clinical progression from Day 0 through Day 7 after sepsis diagnosis, participants will be classified according to the presence or absence of sepsis-associated liver injury (SALI) and sepsis-associated acute kidney injury (S-AKI) for outcome-specific comparative analyses. Participants with neither SALI nor S-AKI will constitute the Sepsis Control subgroup. Participants meeting criteria for both SALI and S-AKI will be included in both outcome-specific analyses. Among participants who develop SALI and/or S-AKI, organ recovery status will also be evaluated at Days 14-20 after sepsis diagnosis.
Healthy adult volunteers (age ≥ 18 years) without chronic underlying diseases (e.g., liver, kidney, or gastrointestinal disorders) and no history of antibiotic or probiotic use within the past month. This cohort serves as a baseline reference cohort to characterize reference gut microbial and metabolic profiles; biospecimens will be collected only once at the time of enrollment.
Association of Longitudinal Trajectories in Fecal Microbial Alpha Diversity With the Occurrence of Sepsis-Associated Acute Kidney Injury
Sepsis-associated acute kidney injury (S-AKI) occurring from Day 0 through Day 7 after sepsis diagnosis will be assessed according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria using serum creatinine and urine output obtained from routine clinical laboratory testing and medical records. Fecal microbial alpha diversity will be measured using the Shannon diversity index (unitless), calculated from metagenomic sequencing and bioinformatic analysis of stool samples collected on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis. Longitudinal trajectories of the Shannon diversity index will be compared between patients with and without S-AKI using linear mixed-effects models accounting for repeated measurements within participants. The primary longitudinal association will be evaluated using the group-by-time interaction term.
Time frame: Fecal microbial alpha diversity assessed on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis; S-AKI assessed from Day 0 through Day 7 after sepsis diagnosis.
Association of Longitudinal Trajectories in Fecal Microbial Alpha Diversity With the Occurrence of Sepsis-Associated Liver Injury
Sepsis-associated liver injury (SALI) occurring from Day 0 through Day 7 after sepsis diagnosis will be assessed using routine clinical laboratory measurements. SALI is defined by at least one of the following: total bilirubin (TBIL) \>2 mg/dL and international normalized ratio (INR) \>1.5; alanine aminotransferase (ALT) ≥5 times the upper limit of normal (ULN); alkaline phosphatase (ALP) ≥2 times ULN; or ALT ≥3 times ULN with TBIL ≥2 times ULN. Fecal microbial alpha diversity will be measured using the Shannon diversity index (unitless), calculated from metagenomic sequencing and bioinformatic analysis of stool samples collected on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis. Longitudinal trajectories of the Shannon diversity index will be compared between patients with and without SALI using linear mixed-effects models accounting for repeated measurements within participants. The group-by-time interaction will represent the longitudinal association.
Time frame: Fecal microbial alpha diversity assessed on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis; SALI assessed from Day 0 through Day 7 after sepsis diagnosis.
Association of Longitudinal Changes in Fecal Microbial Beta Diversity With the Occurrence of Sepsis-Associated Acute Kidney Injury
Sepsis-associated acute kidney injury (S-AKI) occurring from Day 0 through Day 7 after sepsis diagnosis will be defined according to KDIGO criteria using serum creatinine and urine output. Fecal microbial beta diversity will be assessed using Bray-Curtis dissimilarity (unitless) from metagenomic sequencing of stool samples collected on Day 0, Days 3-5, Days 7-10, and Days 14-20. Longitudinal differences in microbial community composition between patients with and without S-AKI will be evaluated using PERMANOVA including group, time, and group-by-time interaction, with repeated measurements accounted for by constrained permutations. The longitudinal association will be reported as the PERMANOVA R² for the group-by-time interaction.
Time frame: Fecal microbial beta diversity assessed on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis; S-AKI assessed from Day 0 through Day 7 after sepsis diagnosis.
Association of Longitudinal Changes in Fecal Microbial Beta Diversity With the Occurrence of Sepsis-Associated Liver Injury
Sepsis-associated liver injury (SALI) occurring from Day 0 through Day 7 after sepsis diagnosis will be assessed according to the prespecified SALI criteria. Fecal microbial beta diversity will be assessed using Bray-Curtis dissimilarity (unitless) from metagenomic sequencing of stool samples collected on Day 0, Days 3-5, Days 7-10, and Days 14-20. Longitudinal differences in microbial community composition between patients with and without SALI will be evaluated using PERMANOVA including group, time, and group-by-time interaction, with repeated measurements accounted for by constrained permutations. The longitudinal association will be reported as the PERMANOVA R² for the group-by-time interaction.
Time frame: Fecal microbial beta diversity assessed on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis; SALI assessed from Day 0 through Day 7 after sepsis diagnosis.
Association of Longitudinal Trajectories in Fecal Microbial Alpha Diversity With Kidney Recovery Status After Sepsis-Associated Acute Kidney Injury
Among patients who develop sepsis-associated acute kidney injury (S-AKI) from Day 0 through Day 7 after sepsis diagnosis, kidney recovery status will be assessed at Days 14-20 relative to baseline serum creatinine. Complete recovery will be defined as serum creatinine \<1.2 times baseline without ongoing kidney replacement therapy (KRT); partial recovery as serum creatinine ≥1.2 but \<1.5 times baseline without ongoing KRT; and non-recovery as serum creatinine ≥1.5 times baseline or ongoing KRT. Fecal microbial alpha diversity will be measured using the Shannon diversity index at the four prespecified time points. Longitudinal trajectories will be compared across kidney recovery categories using linear mixed-effects models accounting for repeated measurements within participants.
Time frame: Fecal microbial alpha diversity assessed on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis; kidney recovery status assessed at Days 14-20.
Association of Longitudinal Trajectories in Fecal Microbial Alpha Diversity With Liver Injury Recovery Status After Sepsis-Associated Liver Injury
Among patients who develop sepsis-associated liver injury (SALI) from Day 0 through Day 7 after sepsis diagnosis, liver injury recovery status will be assessed at Days 14-20 using the prespecified SALI criteria. Recovery will be defined as no longer meeting any SALI criterion; persistent liver injury will be defined as meeting at least one SALI criterion at Days 14-20. Fecal microbial alpha diversity will be measured using the Shannon diversity index at the four prespecified time points. Longitudinal trajectories will be compared between patients with liver injury recovery and those with persistent liver injury using linear mixed-effects models accounting for repeated measurements within participants.
Time frame: Fecal microbial alpha diversity assessed on Day 0, Days 3-5, Days 7-10, and Days 14-20 after sepsis diagnosis; liver injury recovery status assessed at Days 14-20.
Total Plasma Short-Chain Fatty Acid Concentration
Total plasma short-chain fatty acid concentration will be reported as a single aggregate value at each prespecified time point. It will be calculated as the sum of plasma acetate, propionate, and butyrate concentrations, all measured in μmol/L by ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS).
Time frame: Days 0, 3-5, 7-10, and 14-20 after sepsis diagnosis.
Plasma Indoxyl Sulfate Concentration
Plasma indoxyl sulfate concentration will be measured by UPLC-MS/MS and reported in μmol/L at each prespecified time point.
Time frame: Days 0, 3-5, 7-10, and 14-20 after sepsis diagnosis.
Fecal Calprotectin Concentration
Fecal calprotectin concentration will be measured using a validated fecal calprotectin immunoassay and reported in μg/g of stool at each prespecified time point.
Time frame: Days 0, 3-5, 7-10, and 14-20 after sepsis diagnosis.
28-Day All-Cause Mortality
All-cause mortality within 28 days after sepsis diagnosis, reported as the percentage (%) of enrolled sepsis patients who die. Vital status will be ascertained from medical records and follow-up contact.
Time frame: Day 28 after sepsis diagnosis.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2030, 47 months after the start.
Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 47 months is above that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: primary completion Feb 2028 → Feb 2030 and completion Feb 2028 → Mar 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Zhejiang University →